Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2012

View Archived Issues

Novel acetyl-CoA carboxylase 2 inhibitors presented

Taisho reports novel phosphodiesterase 10A inhibitors

Janssen discloses new serotonin 5-HT2B receptor antagonists

Data presented from TRACER and TRAP2P-TIMI 50 vorapaxar trials

Immunotherapy potently reduces LDL cholesterol in phase I trials

Transient receptor potential TRPV1 channel antagonist well tolerated in healthy volunteers

PharmaNeuroBoost clear to commence proof-of-concept PNB-02 trial

Omadacycline noninferior to linezolid in phase III trial

Shionogi and OncoTherapy Science expand licensing agreement

Allergan obtains rights for Ameluz in Spain

ImmunoGen begins phase II IMGN-901 study

Preclinical data support entry of ABTL-0812 into the clinic

ViroMed clear to conduct head-to-head phase III VM-501 study

Roche reports topline data from phase III EMILIA trial

TH-302 gets orphan drug status in E.U. and U.S.

Myriad Genetics and Cephalon enter agreement for mutation testing in phase I/II study

Cardium Therapeutics launches wound care product in U.S.

Portola begins pivotal study of its factor Xa inhibitor

Kyowa Hakko Kirin files application for approval of Parkinson's disease treatment in Japan

Roche divulges novel HDL cholesterol-increasing agents

Novel GCS activators patented by Bayer Schering

First three phase III QVA-149 studies meet primary endpoints

GSK seeks Japanese approval for combination tablet to prevent and treat malaria

Minophagen granted additional rights to bexarotene

Novartis seeks approval for Lucentis line extension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...